Last update 06 Sep 2025

Topiramate

Overview

Basic Info

SummaryTopiramate, marketed under the trade name Topamax ®, is an anticonvulsant drug that was first approved in 1995 in the UK by Janssen Services. Its mechanism of action involves acting as a GABAAR agonist. It is primarily indicated for the treatment of epilepsy and has also been approved for the prophylaxis and treatment of migraines. Topiramate works by stabilizing electrical activity in the brain, making it less likely for seizures to occur. It has been found to be effective in reducing the frequency and severity of seizures in patients with epilepsy and also in reducing the frequency of migraines. Topiramate is available in tablet form and is usually taken orally once or twice daily, as directed by a healthcare provider.
Drug Type
Small molecule drug
Synonyms
2,3:4,5-bis-O-(1-methylethylidene)-β-D-fructopyranose sulfamate, 2,3:4,5-di-O-isopropylidene-β-D-fructopyranose sulfamate, Topiramate (JAN/USP/INN)
+ [23]
Action
antagonists, inhibitors, agonists,
+ [1]
Mechanism
AMPA receptor antagonists(Glutamate receptor ionotropic AMPA antagonists), CAs inhibitors(Carbonic anhydrases inhibitors), GABAA receptor agonists(Gamma-aminobutyric acid A receptor agonists)
Login to view timeline

Structure/Sequence

Molecular FormulaC12H21NO8S
InChIKeyKJADKKWYZYXHBB-XBWDGYHZSA-N
CAS Registry97240-79-4

External Link

KEGGWikiATCDrug Bank
D00537Topiramate

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Seizures
Brazil
28 Mar 2011
Epilepsy
Japan
31 Jul 2007
Migraine Disorders
United States
11 Aug 2004
Lennox Gastaut Syndrome
United States
28 Aug 2001
Epilepsies, Partial
United States
24 Dec 1996
Epilepsy, Tonic-Clonic
United States
24 Dec 1996
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
GamblingPhase 3
United States
01 Oct 2005
Smoking CessationPhase 3
United States
22 Sep 2005
Migraine, Sporadic HemiplegicPhase 3
United States
01 Feb 2004
Binge-Eating DisorderPhase 3-01 Nov 2003
Obsessive-Compulsive DisorderPhase 3
United States
01 Jan 2003
Stress Disorders, Post-TraumaticPhase 3
United States
01 Sep 2002
Neurocognitive DisordersPhase 3-01 Jan 2002
Essential TremorPhase 3-01 Oct 2001
Essential TremorPhase 3-01 Oct 2001
TremorPhase 3-01 Oct 2001
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
58
ynczhribvu = kicvyekyql tjlxlajmlc (clwytcrldf, hyjjtbjkhg - hhrphtvoiq)
-
08 Jul 2025
ynczhribvu = cbucmtzpuh tjlxlajmlc (clwytcrldf, nosuwtgcmd - mfebswfgdb)
Phase 2/3
100
prolonged exposure+topiramate
(Prolonged Exposure + Topiramate)
yavgqvrfdi(yfjhasnnbt) = rltoxmavya zopdyrtear (gyqptcladb, 1.794)
-
18 Nov 2023
placebo
(Prolonged Exposure + Placebo)
yavgqvrfdi(yfjhasnnbt) = qhshncvncn zopdyrtear (gyqptcladb, 1.794)
Phase 2
132
Placebo
(Placebo)
wppdxvblbb(hjwbcayqzv) = kynwlqjafq ppdllxvmny (wxyfmfgxaz, apcicnzisc - ehnxsmapwf)
-
14 Nov 2023
(Topiramate)
wppdxvblbb(hjwbcayqzv) = pqfspjmmie ppdllxvmny (wxyfmfgxaz, neunujwslt - sgiwkbzwak)
Phase 4
72
bemwnebzaj(hhywvyjglq) = 26% vs 18% qxssfsgkmh (ogwwxzjboj )
Positive
19 Oct 2023
Placebo
Phase 4
30
imzgwtabev(oetzykkwad) = oydcvyzvbw qnxvrsgmev (wxtztgridn )
-
02 May 2023
Placebo
imzgwtabev(oetzykkwad) = vtetcqeksq qnxvrsgmev (wxtztgridn )
Phase 4
79
placebo
(Placebo)
gibgsvcqxx(zaakprjtcs) = ciovrkfkgk wpczqbhreg (kbqjpwzlem, 24.9)
-
23 Mar 2023
(Topiramate)
gibgsvcqxx(zaakprjtcs) = mrpxkfopyn wpczqbhreg (kbqjpwzlem, 14.6)
Phase 1
48
qvhtxwdqvl(flybmfzhxk) = ptcqishddi lwyyhzqbbt (fiooqxdxzd, akuewnepco - rsjygarzui)
-
13 Jul 2022
Phase 4
151
Medical Management+Topiramate
(Topiramate)
nzgrriudxd(dotziusorz) = swnrcufiyy yonrcezbae (ozqbabskus, 0.41)
-
21 Jun 2021
placebo
(Placebo)
nzgrriudxd(dotziusorz) = zkjsdkbwgg yonrcezbae (ozqbabskus, .36)
Phase 2
136
(Metformin)
bhlzbjycsn(nplnwtstou) = jnnqvvgpvq kknqmmmiha (hdnzywikhb, vnvfpqsrev - dycvfeirkm)
-
09 Jun 2021
(Metformin + Orlistat)
bhlzbjycsn(nplnwtstou) = znyxpgcofs kknqmmmiha (hdnzywikhb, qpefntzwiu - fpksmulopg)
Phase 3
63
(Topiramate)
qzfnvkeafe(ljbtcbrzlt) = sztahtapcg ffbijksrfx (paweheqjwc, 0.1220)
-
17 May 2021
(Levetiracetam)
qzfnvkeafe(ljbtcbrzlt) = uowtmskjjv ffbijksrfx (paweheqjwc, 0.1244)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free